| Tarrytown Expocare Llc | |
| 8500 Shoal Creek Blvd, Bldg 1, Austin, Texas 78757 | |
| (512) 617-7312 |
| Name | Tarrytown Expocare Llc |
|---|---|
| Organization Name | Tarrytown Expocare Llc |
| Location | 8500 Shoal Creek Blvd, Bldg 1, Austin, Texas 78757 |
| Type | Long Term Care Pharmacy |
| Phone | (512) 617-7312 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.
CarePoint Partners, one of the largest, fastest growing independent home infusion therapy companies in the United States, launched a food drive today throughout its twenty-one locations in eight states to help the less fortunate in the communities where it operates.
The findings reveal that the variant has considerably higher transmissibility and immune escape potential than previously circulating variants and that it can increase the infection fatality rate by 62% - 82% among older adults. The study is currently available on the medRxiv* preprint server.
› Verified 9 days ago
| NPI Number | 1508112392 |
| Organization Name | TARRYTOWN EXPOCARE, LLC |
| Doing Business As | TARRYTOWN EXPOCARE PHARMACY |
| Type | Long Term Care Pharmacy |
| Address | 8500 Shoal Creek Blvd Bldg 1, Austin, TX 78757 |
| Phone Number | 512-617-7312 |
News Archive
Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.
CarePoint Partners, one of the largest, fastest growing independent home infusion therapy companies in the United States, launched a food drive today throughout its twenty-one locations in eight states to help the less fortunate in the communities where it operates.
The findings reveal that the variant has considerably higher transmissibility and immune escape potential than previously circulating variants and that it can increase the infection fatality rate by 62% - 82% among older adults. The study is currently available on the medRxiv* preprint server.
› Verified 9 days ago
| NPI Number | 1669038162 |
| Organization Name | TARRYTOWN EXPOCARE NJ, LLC |
| Type | Long Term Care Pharmacy |
| Address | 1225 Mcbride Ave Ste 102, Woodland Park, NJ 07424 |
| Phone Number | 512-617-7312 |
News Archive
Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.
CarePoint Partners, one of the largest, fastest growing independent home infusion therapy companies in the United States, launched a food drive today throughout its twenty-one locations in eight states to help the less fortunate in the communities where it operates.
The findings reveal that the variant has considerably higher transmissibility and immune escape potential than previously circulating variants and that it can increase the infection fatality rate by 62% - 82% among older adults. The study is currently available on the medRxiv* preprint server.
› Verified 9 days ago
News Archive
Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.
CarePoint Partners, one of the largest, fastest growing independent home infusion therapy companies in the United States, launched a food drive today throughout its twenty-one locations in eight states to help the less fortunate in the communities where it operates.
The findings reveal that the variant has considerably higher transmissibility and immune escape potential than previously circulating variants and that it can increase the infection fatality rate by 62% - 82% among older adults. The study is currently available on the medRxiv* preprint server.
› Verified 9 days ago
360 Wound Solutions, Inc. Type: Durable Medical Equipment & Medical Supplies Supplier Location: 10713 N Ranch Road 620, Austin, Texas 78726 Phone: (512) 276-2044 | |
38th Street Pharmacy Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 711 W 38th St, Austin, Texas 78705 Phone: (512) 458-3784 | |
A&p Quality Care Medical Llp Type: Durable Medical Equipment & Medical Supplies Supplier Location: 8220 Cross Park Dr, Austin, Texas 78754 Phone: (512) 452-5111 | |
Home Respiratory Type: Durable Medical Equipment & Medical Supplies Supplier Location: 4211 Medical Pkwy, Austin, Texas 78756 Phone: (512) 452-0004 | |
American Homepatient Type: Durable Medical Equipment & Medical Supplies Supplier Location: 4030 W Braker Lane, Austin, Texas 78759 Phone: (512) 451-4519 |